Stocktoria

Verastem, Inc. VSTM

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2011-11-08 · LEI

Verastem, Inc. financials (annual)

Revenue
$26.7M $17.5M $88.5M $2.1M $2.6M $10.0M $30.9M 2016201720182019202020212022202320242025
Net income
-$36.4M -$67.8M -$72.4M -$149.2M -$67.7M -$71.2M -$73.8M -$87.4M -$130.6M -$209.5M 2016201720182019202020212022202320242025
Free cash flow
-$29.5M -$76.0M -$138.5M -$33.5M -$53.7M -$104.8M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$30.9M$10.0M$2.6M$2.1M$88.5M$17.5M$26.7M
R&D expense$114.6M$81.3M$61.4M$50.6M$39.3M$41.4M$45.8M$43.6M$46.4M$19.8M
SG&A expense$81.1M$43.6M$30.7M$25.0M$24.1M$62.8M$101.2M$77.3M$21.4M$17.2M
Operating income-$170.1M-$115.0M-$92.1M-$72.9M-$61.4M-$49.4M-$132.3M-$94.8M-$67.8M-$37.0M
Interest expense$1.1M$4.6M$4.1M$2.1M$10.0M$15.8M$20.6M$5.8M$559,000
Income tax$185,000$0$0$194,000$0$0
Net income-$209.5M-$130.6M-$87.4M-$73.8M-$71.2M-$67.7M-$149.2M-$72.4M-$67.8M-$36.4M
EPS (diluted)$-3.02$-3.66$-3.96$-4.57$-4.90$-0.44$-2.00$-1.37$-1.76$-0.99
Operating cash flow-$137.5M-$104.8M-$86.5M-$63.7M-$53.5M-$33.5M-$138.5M-$74.5M-$57.3M-$29.5M
Free cash flow-$104.8M-$53.7M-$33.5M-$138.5M-$76.0M-$29.5M
Cash & equivalents$205.0M$88.8M$77.9M$74.9M$21.3M$67.8M$43.5M$129.9M$82.2M$32.3M
Inventory$1.8M$3.1M$327,000
Total assets$246.4M$101.5M$149.7M$95.0M$108.7M$154.3M$145.0M$277.2M$89.8M$83.6M
Total liabilities$189.2M$130.4M$71.2M$47.7M$21.1M$39.1M$137.9M$152.9M$32.1M$11.3M
Shareholders' equity$57.2M-$28.9M$57.4M$47.4M$87.6M$115.3M$7.2M$124.3M$57.7M$72.3M

Growth · year-over-year · Revenue CAGR 2.5%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+209.1%+26.4%-97.7%+407.1%-34.7%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.